Role of Angiotensin II in Insulin-induced Microvascular Activity

Sponsor

Maastricht University Medical Center (Other)

Overall Status

Completed

CT.gov ID

NCT01024543

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study we hypothesize infusion of Angiotensin II improves the insulin-induced microvascular dilatation and therefore insulin-mediated glucose uptake. Objectives: Does infusion of Angiotensin II increase insulin-mediated glucose uptake via enhanced insulin-mediated microvascular function in healthy subjects?

Condition or Disease	Intervention/Treatment	Phase
Insulin Sensitivity Microcirculation	Drug: Angiotensin II Drug: Phenylephrine Drug: Placebo	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Basic Science

Official Title:

Role of Angiotensin II in Insulin-induced Microvascular Activity

Study Start Date :

Oct 1, 2006

Actual Primary Completion Date :

Nov 1, 2009

Study Completion Date :

Nov 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Sham Comparator: Placebo Placebo	Drug: Placebo
Experimental: Angiotensin II Angiotensin II	Drug: Angiotensin II Angiotensin II
Active Comparator: Phenylephrine Phenylephrine	Drug: Phenylephrine Phenylephrine

Arm

Intervention/Treatment

Sham Comparator: Placebo

Placebo

Drug: Placebo

Experimental: Angiotensin II

Angiotensin II

Drug: Angiotensin II

Angiotensin II

Active Comparator: Phenylephrine

Phenylephrine

Drug: Phenylephrine

Phenylephrine

Outcome Measures

Primary Outcome Measures

functional recruitment of capillaries in the skin [January 2009]

Secondary Outcome Measures

perfused capillary density in the nailfold [January 2009]
Endothelium- (in)dependent vasodilatation of finger skin microcirculation [January 2006]
Insulin sensitivity [January 2009]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

1.18-60 years 2.Caucasian 3.Blood pressure <140/90 mmHg.

Exclusion Criteria:

Obesity (BMI>27kg/m2)
Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
Smoking
Alcohol use >4U/day
Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
Pregnancy
Wearing contact lenses